Risk of Beyaz Blood Clots Higher for Women Under 30, FDA Says
By Andrea Gressman
The FDA has released some concerning news for young women who are currently taking the popular birth control Beyaz. As more Beyaz lawsuits continue to be filed across the nation due to the troubling side effects of Beyaz, these current studies may be an indication that the number of blood clot lawsuits filed over serious Beyaz side effects will not slow down in the near future.
FDA Study on Beyaz Side Effects
A study conducted by the FDA revealed that women under the age of 30 are more susceptible to blood clots, a side effect of Beyaz, than older women taking drospirenone. Drospirenone is one of the active ingredients in Beyaz birth control. The FDA also studied the risk of Beyaz blood clots in pediatric patients, or those under the age of 17. The FDA published a summary of their investigation, indicating that Beyaz birth control was associated with hundreds of adverse event reports and deaths resulting from Beyaz blood clot injuries in women under 30 years old.
The FDA review found 467 reports for Beyaz blood clot side effects, including six reports of Beyaz venous thromboembolisms (VTEs), three reports of Beyaz pulmonary embolism, and one report of retinal thromboembolism caused by Beyaz. Venous thromboembolism and pulmonary embolism are common blood clot injuries reported in Beyaz blood clot lawsuits. The FDA found that 4% of the reports (or 19 patients) involved women under the age of 17.
FDA Issues Warning of Beyaz Blood Clot Side Effects
The FDA issued warnings on the labels of Beyaz and other contraceptives containing drospirenone, stressing that the drospirenone chemical may be associated with an elevated risk of blood clots than contraceptives containing levonorgestrel.
Other FDA reviewers indicated that studies required by regulatory agencies showed no elevated venous thromboembolism (VTE) risk; however, many other epidemiological studies reported a double or triple risk factor for VTE in birth control pills that contain drospirenone compared to other products containing progestin.
Though the FDA’s review of Beyaz birth control uncovered no unexpected evidence of pediatric safety concerns, studies did uncover that a rather sizable portion of women between 10-24 years old have used a contraceptive for non-contraceptive purposes including acne, menstrual pain, and menstrual regulation. Additionally, women under 30 are at higher risk than younger women for developing Beyaz blood clots and venous thromboembolisms.
Do You Have a Beyaz Lawsuit?
If you or someone you love has experienced one or more of the severe side effects associated with the birth control Beyaz, it is critical that you contact an experienced Beyaz lawsuit attorney. Regardless of where you live or what side effects you have experienced, including stroke, pulmonary embolism (PE), blood clots, heart attack, or deep vein thrombosis (DVT), there are qualified Beyaz injury lawyers standing by to hear the details of your case. All you have to do is visit the Yaz/Yasmin, Beyaz & Ocella Birth Control Pill Class Action Lawsuit Settlement & Investigation page and receive your free consultation for your Beyaz lawsuit.
Updated September 19th, 2012
{loadposition content_postads}
All medical device, dangerous drug and medical class action and lawsuit news updates are listed in the Drug and Medical Device section of Top Class Actions.
Top Class Actions Legal Statement
Semaglutide vision loss lawsuit — See if your NAION diagnosis qualifies for compensation
October 7, 2025 | Legal News
